Biotalys

Biotalys is a provider of agrobody foundry and product pipeline services to individuals.

Business Model:

Revenue: $0

Employees: 51-200

Detailed Biotalys Information

Geographic Data

Biotalys headquarters map

Address: Technologiepark-Zwijnaarde 94

City: Ghent

State: flemish brabant

Zip: 9052

Country: BE

Financial Info

Stage:

grant

Raised Last:

$6M

Raised Total:

$54M

Metrics

6,031,115Website Global Rank

1,353Website Monthly Traffic

Twitter Followers

Description

Biotalys is a provider of agrobody foundry and product pipeline services to individuals.

Contact Phone:

Contact Email:

Biotalys went public on 7/2/2021 on the NYSE Euronext

Listed Exchange:
NYSE Euronext

IPO Date:
7/2/2021

IPO Valuation:
$274M

Ticker Symbol:
BTLS

IPO Price:
$8.898633881726477/share

Amount Raised:
$63M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2019 Series C $0 Ackermans &a; van Haaren
PMV
Madeli Participaties
Gimv
Qbic Fund
K &a; E
Sofinnova Partners
Gimv
Agri Investment Fund
Biovest International
VIB
Ackermans &a; van Haaren
PMV
Madeli Participaties
Gimv
Qbic Fund
K &a; E
Sofinnova Partners
Gimv
Agri Investment Fund
Biovest International
VIB
3/2017 Series B $0 Agri Vie
Biovest International
Gimv
Globachem
Madeli Participaties
PMV
Qbic
Sofinnova Partners
VIB
Agri Vie
Biovest International
Gimv
Globachem
Madeli Participaties
PMV
Qbic
Sofinnova Partners
VIB
1/2013 Venture Round $0 Gimv
PMV
Qbic
SoFi
VIB
Gimv
PMV
Qbic
SoFi
VIB
5/2020 Grant 1 $1.8M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
3/2020 Series C 1 $11.2M Novalis LifeSciences
Novalis LifeSciences
Novalis LifeSciences
Novalis LifeSciences
9/2020 Grant $1.3M
7/2021 IPO -
3/2020 Series C $11.1M Novalis LifeSciences
5/2020 Grant $1.7M
7/2019 Series C $39.8M
10/2021 Series C -
10/2020 Grant 1 $1.3M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
10/2021 Grant 1 $6M Bill &a; Melinda Gates Foundation
Bill &a; Melinda Gates Foundation
7/2021 IPO -
10/2021 Series C -
10/2020 Grant 1 $1.3M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
5/2020 Grant 1 $1.8M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
3/2020 Series C 1 $11.2M Novalis LifeSciences
Novalis LifeSciences
Novalis LifeSciences
Novalis LifeSciences
7/2019 Series C 10 $39.1M PMV
Madeli Participaties
Gimv
Qbic Fund
K &a; E
Sofinnova Partners
Gimv
PMV
Madeli Participaties
Gimv
Qbic Fund
K &a; E
Sofinnova Partners
Gimv
3/2017 Series B 9 $11.6M Sofinnova Partners
Sofinnova Partners
1/2013 Venture Round 5 $6.7M Gimv
Gimv
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research